Table Graph
      published meta-analysis   sensitivity analysis   studies

cilgavimab and tixagevimab (Evusheld) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias hospitalizationdetailed resultsPROVENT, 2022 0.04 [0.00; 0.63] 0.04[0.00; 0.63]PROVENT, 202210%4,685NAnot evaluable symptomatic Covid-19detailed resultsPROVENT, 2022 0.23 [0.10; 0.54] 0.23[0.10; 0.54]PROVENT, 202210%5,072NAnot evaluable severe COVID-19 occurrencedetailed resultsPROVENT, 2022 0.25 [0.01; 7.50] 0.25[0.01; 7.50]PROVENT, 202210%5,172NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-04-28 00:52 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 888 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons